B cells and B cell directed therapies in rheumatoid arthritis: towards personalized medicine
Thurlings, R.M.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
COLOR PRINT SECTION
Different patterns of lymphocyte infiltration in representative synovial tissue specimens from patients with rheumatoid arthritis. In some patients, mixed infiltration of aggregates of T and B cells was present (A and C), together with a high number of infiltrating macrophages (C). In other patients, there was diffuse or scarce infiltration of CD3+ T cells (B), and few or no B cells (D), while macrophages were the dominant infiltrating cell population (F). (Original magnification x 20.)
Change in the number of CD22+ B cells in representative serial synovial tissue samples obtained from 2 different rheumatoid arthritis patients before (A and C) and 4 weeks after (B and D) initiation of rituximab treatment. Different patterns of depletion were identified. In some patients, there was complete B cell depletion (compare A and B), while in other patients, few B cells were depleted (compare C and D). (Original magnification x 20.)

Follicular dendritic cells (FDCs) expressing the CD21 long isoform (A), detected in CD22+ B cell-containing lymphocyte aggregates (B). Synovial tissue samples from 8% of the rheumatoid arthritis patients contained lymphocyte aggregates with CD22+ B cells surrounding FDCs. (Original magnification x 20; x 40 in inset.)
CHAPTER 6 FIGURE 5. Change in the number of CD138+ plasma cells in representative serial synovial tissue samples obtained at 4 (A and C) and 16 (B and D) weeks after initiation of rituximab treatment. Different patterns of response were identified. In patients who responded to treatment we observed a reduction in plasma cells between 4 and 16 weeks after treatment (compare A and B), while in patients who did not fulfil the response criteria, plasma cells persisted (compare C and D) (Original magnification x20). Linear regression analysis revealed a significant relationship between the decrease in plasma cell numbers and the decrease in 28-joint Disease Activity Score (DAS28) at week 24.